{"url_path":"/sec/rgnx/8-k/2026-06-03/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1590877/0001193125-26-254590-index.html","accession_number":"0001193125-26-254590","cik":"0001590877","ticker":"RGNX","issuer_name":"REGENXBIO Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1590877/0001193125-26-254590-index.html","primary_entity_key":"0001590877","primary_entity_name":"REGENXBIO Inc."},"word_count":228,"has_tables":true,"body_markdown":"## Item 8.01 Other Events.\n\nOn June 3, 2026, the Company commenced a Stock Option Exchange Program for non-executive employees that was approved by shareholders at the Annual Meeting. The exchange offer period will commence on June 3, 2026 and, unless extended, will conclude on July 1, 2026.\n\n \n\nUnder the program, eligible participants will be able to exchange outstanding stock options granted under the Company’s 2015 Equity Incentive Plan that have an exercise price at or above $18.00, for a reduced number of stock options at a per share exercise price equal to the fair market value of the Company’s common stock on the grant date of the new options, which is expected to be the first business day following the expiration of the exchange offer. The exchange program is not expected to result in a significant change to the Company’s stock compensation expense.\n\n \n\nFor more information, please refer to the Proxy Statement and the Tender Offer Statement that the Company expects to file with the Securities and Exchange Commission on June 3, 2026.\n\n##  \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nREGENXBIO INC.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 3, 2026\n\nBy:\n\n/s/ Patrick J. Christmas II\n\n \n\n \n\n \n\nPatrick J. Christmas II\nExecutive Vice President, Chief Strategy & Legal Officer"}